GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » Net Income From Continuing Operations

PolyPeptide Group AG (XSWX:PPGN) Net Income From Continuing Operations : CHF-49.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. PolyPeptide Group AG's net income from continuing operations for the six months ended in Dec. 2023 was CHF-16.2 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-49.6 Mil.

PolyPeptide Group AG Net Income From Continuing Operations Historical Data

The historical data trend for PolyPeptide Group AG's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG Net Income From Continuing Operations Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial 28.10 33.87 49.18 7.67 -48.51

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.56 10.51 -2.45 -33.43 -16.20

PolyPeptide Group AG Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-49.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG (XSWX:PPGN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » Net Income From Continuing Operations
Comparable Companies
BSP:SNCI11 BSP:OPCT3 BSP:ARML3 BSP:VAMO3 BSP:MILS3 BSP:VLID3 BSP:RENT3 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NBIX NSE:DIVISLAB BOM:500124
Traded in Other Exchanges
PPGNz:UK
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
Website
https://www.polypeptide.com
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines